Home / Health / Retatrutide: Diabetes Drug Sparks Weight Loss Revolution
Retatrutide: Diabetes Drug Sparks Weight Loss Revolution
30 Sep
Summary
- Retatrutide helped Type 2 diabetes patients lose up to 60 pounds.
- The drug is a triple agonist, mimicking three hormones for greater effect.
- It showed significant improvements in blood sugar and obesity markers.
Eli Lilly's experimental drug retatrutide has achieved remarkable weight loss results in late-stage clinical trials for individuals with Type 2 diabetes. Published in The Lancet, the study revealed that participants lost up to 60 pounds, representing about 23% of their body weight. This outcome significantly exceeds the weight loss seen with existing diabetes medications like semaglutide and tirzepatide.
Retatrutide functions as a "triple agonist," targeting three hormones—GLP-1, GIP, and glucagon—a mechanism that distinguishes it from double agonists. In trials, more than half of participants with an average starting BMI of 38 saw their BMI drop below the obesity threshold of 30. Eli Lilly plans to seek FDA approval early next year, with unauthorized versions already appearing on the market, prompting legal action from the company.
Beyond weight loss, retatrutide also demonstrated significant benefits in improving blood sugar control, lowering A1C levels by up to 1.6%. Additional trials showed that retatrutide helped patients without Type 2 diabetes but with obesity lose up to 70 pounds on average. The drug also appears to alleviate symptoms of sleep apnea and knee arthritis pain. Side effects, including nausea and diarrhea, were generally mild to moderate, with a small percentage discontinuing the drug.
